Projects funded by the NCN
Inhibition of activity tryptophan hydroxylase-1 - the new conception in the treatment of mineral and bone disorders in chronić reanal failure.
2013/09/B/NZ7/00046
Keywords:
tryptophan hydroxylase-1 inhibitor serotonin bone and mineral disorders experimental chronic renal failure
Descriptors:
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Uniwersytet Medyczny w Białymstoku, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej
woj. podlaskie
Principal investigator (from the host institution):
Number of co-investigators in the project: 9
Call: OPUS 5 - announced on 2013-03-15
Amount awarded: 729 685 PLN
Project start date (Y-m-d): 2014-03-21
Project end date (Y-m-d): 2018-03-20
Project duration:: 48 months (the same as in the proposal)
Project status: Project settled
Equipment purchased [PL]
- Oprogramowanie Biokinetica v.4.0 (9 000 PLN)
- Aparat spektrofotometr UV-Vis NanoDrop2000.
- Zamrażarka niskotemperaturowa z awaryjnym systemem chłodzenia (CO2), pojemność 500 l, stelaże, pojemniki niskotemperaturowe. (95 000 PLN)
Information in the final report
- Publication in academic press/journals (5)
- Articles in post-conference publications (8)
- Inhibition of peripheral serotonin synthesis by LP533401 and disturbances in calciotropic hormones attenuated excessive osteoblastogenesis with simultaneous improvement of bone mineral status in 5/6 nephrectomized rats.Authors:Pawlak D, Domaniewski T, Sieklucka B, Jakuc M, Pawlak K.Academic press:Biochim Biophys Acta Mol Basis Dis (rok: 2019, tom: 1865, strony: 165528), Wydawca: ElsevierStatus:PublishedDOI:10.1016/j.bbadis.2019.08.004 - link to the publication
- The impact of peripheral serotonin on leptin-brain serotonin axis, bone metabolism and strength in growing rats with experimental chronic kidney disease.Authors:Pawlak D, Domaniewski T, Znorko B, Oksztulska-Kolanek E, Lipowicz P, Doroszko M, Karbowska M, Pawlak K.Academic press:Bone (rok: 2017, tom: 105, strony: 45301), Wydawca: ElsevierStatus:PublishedDOI:10.1016/j.bone.2017.08.004 - link to the publication
- The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism, and bone health in uremic rats.Authors:Pawlak D, Domaniewski T, Znorko B, Pawlak KAcademic press:Expert Opin Ther Targets (rok: 2019, tom: 23, strony: 353-364), Wydawca: Taylor & Francis OnlineStatus:PublishedDOI:10.1080/14728222.2019.1586883 - link to the publication
- The association between elevated levels of peripheral serotonin and its metabolite - 5-hydroxyindoleacetic acid and bone strength and metabolism in growing rats with mild experimental chronic kidney diseaseAuthors:Pawlak D, Oksztulska-Kolanek E, Znorko B, Domaniewski T, Rogalska J, Roszczenko A, Brzóska MM, Pryczynicz A, Kemona A, Pawlak KAcademic press:PLoS One (rok: 2016, tom: 2016;11(10), strony: -), Wydawca: Public Limbrary of ScienceStatus:PublishedDOI:10.1371/journal.pone.0163526 - link to the publication
- LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys.Authors:Pawlak D, Znorko B, Kalaska B, Domaniewski T, Zawadzki R, Lipowicz P, Doroszko M, Łebkowska U, Grabowski P, Pawlak KAcademic press:Bone (rok: 2018, tom: 113, strony: 124-136), Wydawca: ElsevierStatus:PublishedDOI:10.1016/j.bone.2018.05.022 - link to the publication